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Abstract
Oxidative stress plays an important role in the pathogenesis of inflammatory bowel disease (IBD), including Crohn’s disease
(CrD). High levels of Reactive Oxygen Species (ROS) induce the activation of the redox-sensitive nuclear transcription factor
kappa-B (NF-kB), which in turn triggers the inflammatory mediators. Butyrate decreases pro-inflammatory cytokine
expression by the lamina propria mononuclear cells in CrD patients via inhibition of NF-kB activation, but how it reduces
inflammation is still unclear. We suggest that butyrate controls ROS mediated NF-kB activation and thus mucosal
inflammation in intestinal epithelial cells and in CrD colonic mucosa by triggering intracellular antioxidant defense systems.
Intestinal epithelial Caco-2 cells and colonic mucosa from 14 patients with CrD and 12 controls were challenged with or
without lipopolysaccaride from Escherichia Coli (EC-LPS) in presence or absence of butyrate for 4 and 24 h. The effects of
butyrate on oxidative stress, p42/44 MAP kinase phosphorylation, p65-NF-kB activation and mucosal inflammation were
investigated by real time PCR, western blot and confocal microscopy. Our results suggest that EC-LPS challenge induces a
decrease in Gluthation-S-Transferase-alpha (GSTA1/A2) mRNA levels, protein expression and catalytic activity; enhanced
levels of ROS induced by EC-LPS challenge mediates p65-NF-kB activation and inflammatory response in Caco-2 cells and in
CrD colonic mucosa. Furthermore butyrate treatment was seen to restore GSTA1/A2 mRNA levels, protein expression and
catalytic activity and to control NF-kB activation, COX-2, ICAM-1 and the release of pro-inflammatory cytokine. In conclusion,
butyrate rescues the redox machinery and controls the intracellular ROS balance thus switching off EC-LPS induced
inflammatory response in intestinal epithelial cells and in CrD colonic mucosa.
Citation: Russo I, Luciani A, De Cicco P, Troncone E, Ciacci C (2012) Butyrate Attenuates Lipopolysaccharide-Induced Inflammation in Intestinal Cells and Crohn’s
Mucosa through Modulation of Antioxidant Defense Machinery. PLoS ONE 7(3): e32841. doi:10.1371/journal.pone.0032841
Editor: Stefan Bereswill, Charite ´-University Medicine Berlin, Germany
Received November 10, 2011; Accepted January 31, 2012; Published March 6, 2012
Copyright:  2012 Russo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cciacci@unisa.it
Introduction
Intestinal epithelial cells constitute the interface between the gut
lumen and the innate and adaptive immune system [1]. Previous
studies show that a loss of immunologic tolerance is the primary
cause for the development of inflammatory bowel disease (IBD) in
genetically susceptible hosts [1], [2].
IBD is characterized by the loss of tolerance in the intestinal
immune system towards the intestinal microbiota resulting in
constant immune activation which leads to mucosal tissue damage
and chronic inflammation[3]. These spontaneouslyrelapsing chronic
intestinal inflammations are subdivided into two main idiopathic
pathologies ulcerative colitis (UC) and Crohn’s Disease (CrD).
CrD is characterized histologically by transmural inflammation,
epithelial ulceration, fissure formation, and stenosis of segments
throughout the gastrointestinal tract [4]. Increased ROS produc-
tion and decreased antioxidant enzyme levels have been found in
the intestinal mucosa of CrD patients [5], [6], causing increased
oxidative stress, lipid peroxidation and inflammation [7], [8].
Moreover high ROS levels have been reported to promote
activation and translocation of NF-kB [9] into the nucleus through
alternative phosphorylation of Ik-B-a which leads to its ubiqui-
tynation and degradation [9]. This ROS/NF-kB self-sustaining
regulatory loop may contribute to the perpetuation and exacer-
bation of chronic inflammation [10].
CrD therapy is presently based on anti-inflammatory non-
steroid drugs such as mesalazine, steroid analogues, and/or
immuno-suppressive molecules that often produce severe side-
effects [11]. An emerging therapeutic approach is the use of
specific dietary fibre and/or prebiotics able to enhance butyrate
production in the colon of CrD patients [12]. These functional
foods have proven effective in delivering butyrate to the colonic
mucosa, a process that is difficult to achieve by direct
administration of butyrate, either orally or rectally [13]. Butyrate
is a four-carbon short-chain fatty acid produced by bacterial
fermentation of mainly undigested dietary carbohydrates within
the colonic lumen. Although butyrate has been the favoured
energy source for colonic epithelial cells and induces changes in
gene expression influencing colonic function [14],[15], it has
recently been demonstrated to have an anti-inflammatory effect
[16]. In two in vitro studies, butyrate was shown to modulate
inflammation through NF-kB inhibition [17] and up-regulation of
PPAR-c [18]. Several in vivo studies report a decreased
inflammation after rectal administration of butyrate or mixtures
of SCFA (short chain fatty acids) in patients with active ulcerative
colitis [19],[20] and diversion colitis [21],[22]. However, the
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remain unclear.
Since the impaired mucosal anti-oxidative capacity may further
promote intestinal inflammation in patients with IBD [23], this
study aimed to investigate whether butyrate could modulate GST-
A1/A2 mRNA levels, protein expression and catalytic activity and
readjust ROS levels, thus switching off ROS mediated NF-kB
activation and the inflammatory response in intestinal epithelial
Caco-2 cells and CrD colonic mucosa.
Materials and Methods
Patients and ex-vivo organ cultures
Biopsy specimens were taken from uninflamed mucosal areas
immediately next to inflamed tissues of fourteen patients with CrD
(n=14, mean age 24 years, range 18–41). The primary site of
involvement was ileal in four patients, ileocolonic in four and
colonic in five. Disease was active in all patients, as defined by a
Crohn’s Disease Activity Index (CDAI) of .150 [24]. Normal
controls (n=12, mean age 22.4 years, range 18–29) included
mucosal samples taken from eight patients with uncomplicated
diverticular disease and four patients with rectal bleeding due to
haemorrhoid. Informed written consent was obtained from all
subjects, and the protocol of the study was approved by the Ethics
Committee of Regione Campania Health Authority. One
specimen from each patient was used for diagnosis; the other
samples were cultured in vitro for 4 and 24 h [25] with medium
alone, EC-LPS (1 mg/ml E. Coli Serotype O127: B8 Lipopoly-
saccharide, Sigma-Aldrich, Milan, Italy) in the presence or
absence of the butyrate (10 mM).
Cell lines
Caco-2 cells, a human colonic epithelial cell line, were cultured
as recommended by the American Type Culture Collection
(ATCC). Experiments were initiated on day 14 or 15 after seeding
and continued for 24–72 h, as the cells progressed through more
mature stages of differentiation.
Cell cultures
Cells were seeded onto 12-well plates at a density of 2–
3610
5cells/cm
2 and were pre-treated with butyrate (10 mM) for
24 h and finally stimulated with EC-LPS (1 mg/ml
21) for another
4 h and 24 h.
RNA interference
Cells were seeded onto 12-well plates (CostarH, Corning) at a
density of 2–3610
5cells/cm
2. The cells were transfected with
human GSTA1/A2 or scrambled small interfering RNA
(50 nmol/L, siRNA) duplex using Lipofectamine RNAiMAX at
37uC for 72 h. Cells were then stimulated in the presence of
butyrate with EC-LPS for 4 h and 24 h. The GSTA1/A2 duplex
siRNA was a pool of two sequences: siRNA no. 1, GSTA1 (catalog
number HSS142318, Invitrogen, Milan, Italy) and siRNA no. 2,
GSTA2 (catalog number HSS142323, Invitrogen, Milan, Italy)
Quantitative RT–PCR
Total RNA was extracted using the RNA-easy Mini Kit
(Qiagen). The mRNA was reverse transcribed with a Super-
ScriptTM III First Strand Synthesis System (Invitrogen). Quan-
titative RT–PCR was performed with an iCycler iQ Multicolour
Real-Time PCR Detector (Bio-Rad) with iQ TM SYBR Green
supermix (Bio-Rad). Expression levels of genes were normalized to
b-actin levels in the same sample. Primer sequences were as
follows (59 to 39, sense, antisense): GSTA1, Forward primer CCT
GCC CAC AGT GAA GAA GT Reverse primer GCC TCC
ATG ACT GCG TTA TT; GSTA2, Forward primer GGC TGC
AGC TGG AGT AGA GT Reverse primer ATTGGCACT-
TGCTGGAACAT; b-Actin, Forward primer TGACCCAGAT-
CATGTTTGAG Reverse primer TAATCTCCTTCTG-
CATCCTG. The relative amounts of mRNA were calculated by
using the comparative Ct method.
Nuclear protein extraction
The cells were collected in cold buffer A (10 mmol/L HEPES
(pH 7.9), 1.5 mmol/L MgCl2, 10 mmol/L KCl, and 1 mmol/L
dithiothreitol (DTT) and protease inhibitor cocktail), homogenized
in Potter-Elvehjem pestle and glass tube (Sigma-Aldrich), and
centrifuged at 11,0006g for 20 min at 4uC to obtain nuclear pellets.
Supernatants were collected as cytoplasmic fractions. Nuclear pellets
were washed with buffer A and resuspended inbuffer B (20 mmol/L
HEPES (pH 7.9), 1.5 mmol/L MgCl2, 0.42 mol/L NaCl,
0.2 mmol/L EDTA, 25% (v/v) glycerol, 1 mmol/L DTT, and
protease inhibitor cocktail) and incubated on ice for 50 min with
occasional mixing to extract nuclear proteins. Nuclear extracts were
cleared by centrifugation (11,0006 g, 15 min, 4uC), and superna-
tants were collected as nuclear fraction. Then, cytoplasmic and
nuclear whole-cell fractions were analyzed by immunoblotting.
Immunoblot
Experiments were carried out as previously described [26].
Briefly,cells were washedinice-cold phosphate-buffered saline (PBS)
and lysed with NP-40 lysis buffer (1% NP-40, 150 mmol/L NaCl,
50 mmol/LTris, pH 7.4,10 mmol/LNaMoO4)a t4 uCf o r3 0m i n .
Protease inhibitors were added to NP-40 lysis buffer to a final
concentration of 1 mg
.ml
21 leupeptin, 2 mg
.ml
21 aprotinin,
50 mg
.ml
21 Pefabloc, 121 mg
.ml
21 benzamidine, 3.5 mg
.ml
21 E64.
Celllysateswerecentrifugedat maximalspeedinaneppifugeat4uC,
and supernatants were collected. Cell lysates (50 mg) were loaded,
separated on 10% SDS-PAGE and transferred to nitrocellulose.
After blocking for 2 h (TBS/Tween supplemented with 5% nonfat
dry milk), blots were incubated with anti-phospho-p65NF-kB(Cell
Signaling Technology, Danvers, Massachusetts, USA), Gluthatione-
S-transferase a (goat polyclonal IgG, Abcam, Milan,Italy), phospho-
p42/p44 MAP kinases (rabbit polyclonal IgG, Cell Signaling
Technology), COX-2 (Cell Signaling Technology, Danvers, Massa-
chusetts, USA), ICAM-1 (SantaCruz Biotechnology, Santa Cruz,
California, USA) and b-actin (rabbit polyclonal IgG; Santa Cruz,
CA, USA) and ab-tubulin (rabbit polyclonal IgG; Santa Cruz, CA,
USA). The primary antibodies were counterstained using a
horseradish peroxidase-conjugated anti-IgG antibody (Amersham,
Little Chalfont, UK) for 60 min at room temperature. Proteins were
visualized by chemiluminescence (ECL Plus, Amersham) and
exposed to X-OMAT film (Eastman Kodak, Rochester, NY).
Protein concentrations were determined using a Bio-Rad protein
assay to ensure equal protein loading prior to Western blot analysis.
Immunolocalization
Human tissue sections. Five mm thick cryostat sections were
fixed in acetone for 10 min. The sections were individually
incubated for 2 hours at room temperature with the following
antibodies: phopsho-p65NF-kB(Ser536) (rabbit polyclonal; Cell
Signaling Technology), p42/p44 MAPK (rabbit polyclonal IgG ;
Cell Signaling Technology), COX-2 (rabbit polyclonal; Cell
Signaling Technology, Danvers, Massachusetts, USA) and
ICAM-1 (rabbit polyclonal; SantaCruz Biotechnology, Santa
Cruz, California, USA). Antigen expression and distribution was
visualized using a donkey anti-rabbit IgGs conjugated to Alexa
Fluor 488 for 60 min at room temperature. Isotype control
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isotype-matched antibodies against inappropriate blood group
antigens were used as control of specificity. Data were analyzed
under fluorescence examination using a LSM510 Zeiss confocal
laser scanning unit (Carl Zeiss, Germany). COX-2 or ICAM-1
positive mononuclear cells (MNC) were counted per mm
2 of
mucosa. Epithelial cells with nuclear p65 localization were
counted per 100 epithelial cells. Data were examined in a blind
fashion by two independent reviewers totally unaware of all the
culture conditions to prevent bias in their observation [27],[28].
Measurement of intracellular reduced glutathione (GSH)
Intracellular GSH levels were measured in Caco-2 cells using a
fluorometric method as described by Ranganna et al. [29]. Briefly,
cells were collected in ice-cold NaCl/Pi were pelleted by
centrifugation (750 g, 5 min, 4uC). The pellets were suspended
in buffer A (50 mL of 25% (w/v) metaphosphoric acid and
188 mL of 0.1 mmol/L sodium phosphate buffer supplemented
with 5 mmol/L EDTA, pH 8.0) and homogenized on ice. The
homogenates were centrifuged (15,000 g, 20 min, 4uC) and
diluted 10-fold with 0.1 mL sodium phosphate buffer B
(5 mmol/L EDTA, pH=8.0) incubated with buffer C (1.8 mL
buffer B and 0.1 mL 0.1% o phthalaldehyde solution in methanol )
for 15 min at room temperature. Changes in fluorescence were
analyzed with a Wallac 1420 multilabel Counter (PerkinElmer
Waltham, MA, USA) at an activation wavelength of 350 nm and
an emission wavelength of 420 nm. Cellular GSH levels were
calculated using standard curve measurements performed simul-
taneously with the samples and expressed as pmole of GSH/cell.
ROS detection
The cells and five-micrometer cryostat sections were pulsed with
10 mmol/L 5-(and-6)-chloromethyl-2979-dichlorodihydrofluores-
cein diacetate acetyl ester (CM-H2DCFDA) (Molecular Probes,
Invitrogen) [26]. CM-H2DCFDA, a ROS-sensitive probe, was
used to track changes in the cellular redox state. The cells were
analyzed with a Wallac 1420 multilabel Counter (PerkinElmer
Waltham, MA,USA) and detected by a LSM510 Zeiss confocal
laser scanning unit (Carl Zeiss, Germany).
ELISA
TNF-a secretion was measured using the BD OptEIATM
ELISA kit II (BD Biosciences) according to the manufacturer’s
instructions. Protein concentrations of whole-cell lysates were
measured using the BioRad Dc protein Assay (BioRad). TNF-a
levels were normalized to standard protein concentrations [30].
Statistical analysis
All of the experiments were performed in duplicate and
repeated at least three times. Group data from all experiments
are presented as means 6 s.d. . One-way ANOVA was used for all
of the statistical analyses among multiple groups. In another set of
data the paired two tailed Student’s test was used for statistical
analyses. Groups were compared by post hoc Tukey-Kramer test.
A probability of P-value,0.05 was considered significant.
Results
Effect of butyrate on GSTA1/A2 mRNA levels, protein
expression and catalytic activity and ROS levels in
intestinal epithelial cells upon challenge with LPS from
Escherichia Coli
We demonstrated that butyrate prevents LPS-induced decrease
of GSTA1/A2 mRNA, protein and activity in LPS-stimulated
intestinal epithelial cells (Figure 1A and B and Figure S1A). To
establish that butyrate induces GST expression in lipopolysaccha-
ride stimulated Caco-2 cells, the influence of an siRNA construct
specific to GSTA1/A2 was evaluated. Results showed that
butyrate-induced GST-a protein (Figure S1B and Figure 1D)
was almost completely silenced when Caco-2 cells were transfected
with GST A1/A2 siRNA prior to stimulation with butyrate
whereas negative siRNA transfection had no relevant effect on
butyrate-induced GST expression (Figure S1B).
Using a well established tissue culture model for biopsy of
human CrD colonic mucosa [28], we showed that butyrate
prevents LPS-induced decrease of GSTA1/A2 mRNA, protein
and activity in LPS-treated colonic mucosa in CrD patients
(Figure 1C and D and Figure S1C).
Since glutathione-S-transferases (GSTs) play an important role
in protection mechanisms against oxidative stress, we investigated
the capacity of butyrate-induced GST-a expression to attenuate
lipopolysaccharide-mediated oxidative stress in intestinal epithelial
cells and CrD colonic mucosa.
We demonstrated that butyrate was effective in controlling the
increase of ROS levels and attenuating the concomitant decline in
reduced glutathione (GSH) levels generated in response to
lipopolysaccharide in intestinal epithelial cells (Figure 2A and
Figure S2A). GSTA1/A2 siRNA antagonized the down-regulatory
effect of the butyrate on ROS levels and decline in GSH levels
induced by EC-LPS (Figure 2A and Figure S2A). We investigated
the effect of butyrate in controlling oxidative stress in CrD
epithelia. Before challenge, higher ROS levels were observed in
CrD colonic mucosa compared with controls. EC-LPS challenge
led to an increase of ROS levels at 4 hours of incubation in CrD
colonic mucosa but not in controls (Figure 2B). Moreover
treatment of cultured biopsies with butyrate was highly effective
in preventing LPS-induced ROS levels (Figure 2B).
A pro-oxidative environment induces activation of different
stress sensitive signalling pathways [31],[32],[33]. We demonstrat-
ed that butyrate prevented ROS-induced p42/p44 MAPK
phosphorylation in LPS-stimulated intestinal epithelial cells.
(Figure 2C). GSTA1/A2 siRNA antagonized the effect of butyrate
in decreasing p42/p44 MAPK phosphorylation (Figure S2B).
We investigated the effect of butyrate in controlling ROS-
induced p42p/44 MAPK phosphorylation in epithelia of CrD
patients. Before challenge, higher p42/p44 MAPK phosphoryla-
tion was observed in CrD colonic mucosa compared with controls
(Figure 2D). EC-LPS challenge led to an increase of p42/p44
MAPK phosphorylation at 4 h of incubation in CrD colonic
mucosa but not in controls (Figure 2E and F). The increased
expression of p42/p44 MAPK phosphorylation following EC-LPS
challenge was efficiently controlled by butyrate (Figure 2E and F),
which also reduced basal p42/p44 MAPK phosphorylation
observed in the absence of any EC-LPS stimulation (Figure S3A
and S3B).
Butyrate decreases ROS mediated NF-kB activation and
inflammatory response in intestinal epithelial Caco-2 cells
upon challenge with LPS from Escherichia Coli
Since ROS levels enhance the signal transduction pathways for
NF-kB activation in the cytoplasm and translocation into the
nucleus, we examined whether butyrate is able to attenuate ROS-
mediated NF-kB activation in Caco-2 cells challenged with EC-
LPS. We demonstrated that butyrate was effective in controlling
the translocation of phosphorylated p-65- NF-kB into nuclear
extracts (Figure 3A) after 4 h and up to 24 h (data not shown) of
challenge with EC-LPS. GSTA1/A2 siRNA antagonized the
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NF-kB induced by EC-LPS (data not shown).
Since activation of the NF-kB/Rel transcription family plays a
central role in inflammation through its ability to induce
transcription of pro-inflammatory genes, we investigated whether
butyrate is able to dampen down inflammatory response in Caco-2
cells challenged with EC-LPS. We showed that butyrate was
effective in controlling COX-2, ICAM1 protein expression and
TNF-a release induced by EC-LPS (Figure 3B and C). GSTA1/
A2 siRNA antagonized the down-regulatory effect of the butyrate
on COX-2, ICAM-1 protein levels and TNF-a release induced by
EC-LPS (data not shown).
Butyrate decreases ROS mediated NF-kB activation and
mucosal inflammation in CrD mucosal epithelial cells
upon challenge with LPS from Escherichia Coli
Weinvestigated the effect of butyrate in controlling ROS mediated
mucosal inflammation in CrD colonic mucosa. Before challenge,
higher numbers of epithelial cells with p-65-nuclear localisation were
observed in CrD colonic mucosa compared with controls (Figure 4
A). EC-LPS challenge led to an increase in numbers of epithelial cells
with p-65-nuclear localisation at 4 h of incubation in CrD colonic
mucosa but not in controls (Figure 4D). Moreover treatment of
cultured biopsies with butyrate was highly effective in controlling EC-
LPS induced p-65-nuclear localisation (Figure 4A).
Figure 1. Effect of butyrate on GSTA1/A2 mRNA levels and protein expression in intestinal epithelial cells and CrD mucosal
epithelial cells challenged with LPS from Escherichia Coli. (A–B) Caco-2 cells were treated for 24 hours with butyrate and then were stimulated
with EC-LPS for 4 h. (A) Real time PCR of GSTA1/A2 mRNA. Values are means 6 s.d., n=6. Asterisks indicate that means differ from samples cultured
with medium alone and from samples cultured with EC-LPS. *P,0.05. (B, top line) Immunoblot of GST-a. b-actin was used as loading control for blot.
(B, bottom line) Densitometric analysis of the band intensity. Values are means 6 s.d., n=6. (C–D) CrD colonic mucosa were cultured for 4 h in the
presence of medium alone, medium with EC-LPS or EC-LPS with butyrate. (C) Real time PCR of GSTA1/A2 mRNA. Values are means 6 s.d., n=14.
Asterisks indicate that means differ from samples cultured with medium alone and from samples cultured with EC-LPS. *P,0.05. (D) confocal
microscopy of GST-a protein (green) in CrD colonic mucosa (n=14). Nuclei counterstained with DAPI(blue). Scale bar, 10 mm.
doi:10.1371/journal.pone.0032841.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32841Figure 2. Effect of butyrate on oxidative stress in intestinal epithelial cells and CrD mucosal epithelial cells challenged with LPS
from Escherichia Coli. Caco-2 cells were treated for 24 h with butyrate or transfected with either 50 nM human GST-a siRNA or scrambled
oligonucleotides and then challenged with EC-LPS for 4 h. (A) Intracellular ROS levels. Values are means 6 s.d., n=6. Asterisks indicate that means
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levels in control (n=10) and CrD colonic mucosa (n=14) before challenge and after challenge with medium alone, medium with EC-LPS or EC-LPS
with butyrate following 4 h of incubation. Values are means 6 s.d. . Asterisks indicate that means differ from control samples, CrD samples cultured
with medium alone and from CrD samples cultured with EC-LPS. *P,0.05. 29,79-dichlorodihydrofluorescein (DCF). (C) Caco-2 cells were treated for
24 h with butyrate and then were stimulated with EC-LPS for 4 h. (C, left panel) Immunoblot of p42/p44 phosphorylation. (C, right panel)
Densitometric analysis of the band intensity. Values are means 6 s.d., n=6. b-actin was used as loading control for blot. (D–E) Confocal microscopy
of phosphorylated p42/p44 (green) and number (F) of epithelial cells with phosphorylated p42/p44 per 100 epithelial in control (n=10) and in CrD
colonic mucosa (n=14) before challenge (D) and after challenge with medium alone, medium with EC-LPS or EC-LPS with butyrate following 4 h of
incubation(E–F). Nuclei counterstained with DAPI (blue). Scale bar, 10 mm. Values are means 6 s.d.. Asterisks indicate that means differ from control
samples, CrD samples cultured with medium alone and from CrD samples cultured with EC-LPS. *P,0.05.
doi:10.1371/journal.pone.0032841.g002
Figure 3. Effect of butyrate on NF-kB activation and inflammatory response in intestinal epithelial cells challenged with LPS from
Escherichia Coli. Caco-2 cells were treated for 24 h with butyrate and then were stimulated with EC-LPS for 4 h. (A) Immunoblot analysis of phospho-
p65(Ser536) in cytoplasmic (C) and nuclear (N) cell fractions. ab-tubulin and laminB were used as protein loading respectively for cytoplasmic and
nuclear extract. (B–C) Caco-2 cells were treated for 24 h with butyrate and then were stimulated with EC-LPS for 24 h. (B, left panel) Immunoblot of
COX-2 and ICAM-1. b-actin was used as loading control. (B, right panel) Densitometric analysis of the band intensity Values are means 6 s.d., n=6.
Asterisks indicate that means differ from samples cultured with EC-LPS. *P,0.05. (C) TNF-a protein. Values are means 6 s.d., n=6. Asterisks indicate
that means differ from samples cultured with EC-LPS. *P,0.05.
doi:10.1371/journal.pone.0032841.g003
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CrD biopsies cultured in the absence of any EC- LPS stimulation
(Figure S3C). To determine whether butyrate is able to switch off the
mucosal inflammation in human EC-LPS stimulated CrD colonic
mucosa, we also analysed the release of pro-inflammatory cytokines,
such as TNF-a and COX-2 or ICAM-1 by mucosal mononuclear
cells. This latter marker was studied as a broad factor of inflammation
as described in previous study [28]. After 24 h of incubation, EC-LPS
also induced an increase of ICAM-1 and COX-2 positive
mononuclear cells and TNF-a release (Figure 4B, C and D) in CrD
colonic mucosa compared with samples cultured in medium alone.
The increased expression of ICAM-1, COX-2 and pro-inflammatory
cytokine, as TNF-a release, following challenge with EC-LPS was
efficiently controlled by butyrate (Figure 4B, C and D). Minimal
TNF-a up-regulation and release, ICAM-1 and COX-2 were
observed in controls after challenge with EC-LPS (data not shown).
Figure 4. Effect of butyrate on mucosal inflammation in CrD mucosal epithelial cells challenged with LPS from Escherichia Coli. (A)
Number of epithelial cells with p65 nuclear localisation per 100 epithelial cells in control (n=10) and CrD colonic mucosa (n=14) before challenge
and after challenge with medium alone, medium with EC-LPS or EC-LPS with butyrate following 4 h of incubation. Nuclei counterstained with DAPI
(blue). Scale bar, 10 mm. Values are means 6 s.d.. Asterisks indicate that means differ from control samples, CrD samples cultured with medium alone
and from CrD samples cultured with EC-LPS. *P,0.05. (B) Confocal microscopy of COX-2 (green) and ICAM-1(green) and number (C) of COX-2 and
ICAM-1 positive lamina propria cells per mm
2 of mucosa in CrD colonic mucosa (n=14) after challenge with medium alone, medium with EC-LPS or
EC-LPS with butyrate following 24 h of incubation. Nuclei counterstained with DAPI (blue). Scale bar, 10 mm. Values are means 6 s.d., n=14. Asterisks
indicate that means differ from samples cultured with medium alone and from samples cultured with EC-LPS. *P,0.05. (D) TNF-a protein after
challenge with medium alone, medium with EC-LPS or EC-LPS with butyrate following 24 h of incubation. Values are means 6 s.d., n=14. Asterisks
indicate that means differ from samples cultured with medium alone and from samples cultured with EC-LPS. *P,0.05.
doi:10.1371/journal.pone.0032841.g004
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This report describes the relationships among a bacterial
product, oxidative stress and mucosal inflammation in the mucosa
of patients with CrD. We have identified butyrate’s role in
intestinal epithelial homeostasis by promoting anti-oxidative
responses and inhibiting mucosal inflammation in the colon of
CrD patients.
The short-chain fatty acid butyrate, which is mainly produced
in the lumen of the large intestine by the fermentation of dietary
fibers, plays a major role in the physiology of the colonic mucosa.
It is also the major oxidative substrate for the colonocyte [34].
Impairment of IEC energy homeostasis is a typical feature of
inflamed tissue in CrD. Constitutive energy expenditure mediated
by persistent IEC activation and reduced energy supply may be
the main causes of failure of IEC to preserve energy homeostasis
[35].
Several studies report decreased butyrate oxidation in the
inflamed mucosa of patients suffering from UC [36] or CrD [37]
and in animal models of experimental colitis [38]. Although other
studies found no defect in butyrate oxidation during IBD
[39],[40],[41].
Previous studies in active IBD and in experimental DSS-colitis
have shown that intestinal inflammation specifically affects
butyrate metabolism [42],[43],[44]. Moreover, down-regulation
of the Monocarboxylate Transporter 1 (MCT-1) is involved in
butyrate deficiency in inflamed colonic mucosa of patients with
IBD and of rats [45]. Thus, a decrease in MCT1 expression,
which reduces the intracellular availability of butyrate [46] could
affect not only its oxidation but also its cell regulatory effects.
Impaired energy availability as well as reduced tissue oxygen
supply and the generation of intra and extracellular free radicals
have also been to induce oxidative stress [47].
ROS are highly toxic to cells and oxygen radical formation in
excess of physiological amounts may overtax the limited intestinal
antioxidant defense system initiating oxidative injury to the gut
[48] inducing damage to lipids, proteins and/or DNA. Moreover,
increased oxidative stress has been seen to destroy the mucosal
barrier of intestinal epithelial cells, increasing permeability.
Different antioxidant defense mechanisms, including enzymatic
antioxidant molecules, such as glutathione-S-transferase (GST)
and non-enzymatic antioxidant molecules such as glutathione
(GSH) are involved in protection against ROS. Deterioration of
anti-oxidative glutathione metabolism [49] and increased colonic
oxidative damage to proteins and DNA in association with
impaired enzyme activity of Cu-Zn superoxide dismutase has been
reported previously in patients with CrD [50]. Our studies
demonstrate that butyrate was effective in controlling the increase
of GSH reduced by EC-LPS in intestinal epithelial Caco-2 cell and
in mucosal biopsies of CrD patients.
There is limited evidence of butyrate’s role in controlling
oxidative stress in the colonic mucosa. In two in vitro studies, pre-
treatment of isolated rat [51] or human [51] colonocytes with
butyrate reduced H2O2-mediated DNA damage. Since the
butyrate’s antioxidant role is not primary, it may be secondary,
influencing DNA repair systems and levels of enzymatic or non-
enzymatic antioxidants. Fermentable fiber uptake in a rat model of
TNBS-induced colitis [52] is reported to increase colonic
concentrations of butyrate, to decrease colonic myeloperoxidase
(MPO) activity and to restore colonic GSH concentration [53].
We demonstrated that butyrate was effective in controlling the
decrease of GST-a protein levels and activity induced by LPS in
intestinal epithelial Caco-2 cells and in mucosal biopsies of CrD
patients. GST is a detoxifying enzyme system that provides
defense against oxidative stress compounds [54]. Since oxidative
stress induces the impairment of the intracellular ROS balance, we
evaluated whether butyrate reduces ROS levels and ROS-
mediated stress sensitive signalling pathways induced by EC-LPS
in Caco-2 cells and in mucosal biopsies of CrD patients. We
demonstrated that butyrate was effective in controlling the
increase of ROS levels and reduces ROS-mediated p42/44
MAPK phosphorylation.
The most extensively studied intracellular pathway that is a target
of ROS and oxidative stress is the transcription factor NF-kB [55].
NF-kB is found in cytoplasm and is bound to Ik-Ba, which prevents
it from entering the nuclei [56]. When these cells are stimulated,
specific kinases phosphorylate Ik-Ba, causing its rapid degradation
by proteasomes [56]. Activation of NF-kB acts on genes for
proinflammatory cytokines, chemokines (chemotactic cytokines that
attract inflammatory cells to sites of inflammation) [56], enzymes
that generate mediators of inflammation, immune receptors, and
adhesion molecules that play a key role in the initial recruitment of
leukocytes to sites of inflammation. Moreover, infiltrating macro-
phages and neutrophils that are abundantly present in inflamed gut
expose the inflamed intestine to substantial oxidative stress by
production of ROS [8] sustaining a vicious circle that leads to a
progressive and uncontrolled inflammatory response. Our results
demonstrate that butyrate controlled ROS-mediated p65 NF-kB
activation in intestinal epithelial Caco-2 cells after challenge with
LPS from Escherichia Coli. Since activation of the NF-kB/Rel
transcription family plays a central role in inflammation through its
ability to induce transcription of pro-inflammatory genes, we
showed that butyrate decreases COX-2, ICAM1 protein expression
and TNF-a release induced by EC-LPS.
To provide the rationale and the proof-of-principle for using
butyrate in CrD patients, we checked whether the mechanisms we
observed in cell lines also take place in human CrD colons. Our
approach to testing potential anti-inflammatory strategies in CrD,
which we have used to study other inflammatory conditions and
potential strategies to modulate the inflammatory response [12], is
based on an ex vivo organ tissue culture model. This model
represents a good approximation to in vivo studies since, all the
anatomical connections in cultured biopsy tissues, are retained and
all cell types (epithelial, myeloid, lymphoid) interact with
neighboring cells within their natural environment. For this study
we have used colonic mucosal biopsies which are routinely
removed surgically.
We demonstrate that, in all CrD colonic tissues, butyrate
reduced p65 phosphorylation and release of pro-inflammatory
cytokines, such as TNF-a and COX-2 or ICAM-1 from mucosal
mononuclear cells, thus restoring the pattern observed in controls
after challenge with LPS from Escherichia Coli. Our study suggests
that the restoration of intracellular ROS balance through
appropriate control of the redox machinery may be a novel
approach to treatment of CrD and may pave the way for the
development of a new class of functional foods that, by enhancing
butyrate production, could be effective treatments for CrD.
Supporting Information
Figure S1 Effect of butyrate on GST-a activity in EC-LPS
stimulated intestinal epithelial cells and Crohn’s muco-
sa. (A) Intracellular GST catalytic enzyme activity was assessed by
conjugation of chloro-2,4-dinitrobenzyne with reduced GSH.
Asterisks indicate that means differ from samples cultured with
medium alone and from samples cultured with EC-LPS. *P,0.05.
(B) Caco-2 cells were transfected with either 50 nM human
GSTA1/A2 siRNA or scrambled oligonucleotides and then
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32841challenged with butyrate for 24 hours. (B, left panel) Immunoblot of
GST-a. b-actin was used as loading control. (B, right panel)
Densitometric analysis of the band intensity. Values are means 6
s.d., n=6. (C) Intracellular GSH activity in butyrate treated CrD
mucosal epithelial cells stimulated with EC-LPS. Asterisks indicate
that means differ from samples cultured with medium alone and
from samples cultured with EC-LPS. *P,0.05.
(EPS)
Figure S2 Effect of butyrate on stress sensitive signalling
pathways in EC-LPS stimulated intestinal epithelial cells.
Caco-2 cells were cultured with butyrate or transfected with either
50 nM human GST-A1/A2 siRNA or scrambled oligonucleotides
and then challenged with EC-LPS. (A) Intracellular GSH levels.
Asterisks indicate that means differ from samples cultured with
medium alone and from samples cultured with EC-LPS. *P,0.05.
(B, left panel) Immunoblot of p42/p44 phosphorylation in Caco-2
cells challenged with EC-LPS. b-actin was used as loading control.
(B,rightpanel)Densitometricanalysisofthe band intensity.Valuesare
means6 s.d., n=6. b-actin was used as loading control for blot.
(EPS)
Figure S3 Expression of phosphorylated p42/p44-MAPk
and p65-NF-kB in Crohn’s mucosa. Confocal microscopy of
phosphorylated p42/p44 (green) (A) and number of epithelial cells
(B) with phosphorylated p42/p44 per 100 epithelial in CrD
colonic mucosa (n=14) Nuclei counterstained with DAPI (blue).
Scale bar, 10 mm. Values are means6 s.d.. Asterisks indicate that
means differ from CrD samples cultured with medium alone.
*P,0.05. (C) Number of epithelial cells with p65 nuclear
localisation per 100 epithelial in CrD colonic mucosa (n=14).
Nuclei counterstained with DAPI (blue). Scale bar, 10 mm. Values
are means6 s.d.. Asterisks indicate that means differ from CrD
samples cultured with medium. *P,0.05.
(EPS)
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